Micap Share Discussion Threads

[xxxyyy] 15/1/2005 10:40

article in telegraph from gh director of bprg, in it says first of his products will be stop smoking strips. done deal as i read it
.

[fuzzyduck04] 11/1/2005 11:39

28th February. 6 month contract negotiation expires with Bioprogress. 7 weeks off!

Quack

[matthu] 07/1/2005 21:08

Some people get scared out of their holdings by looking at the downward trend of the share price - this is a share that will only really appreciate once it turns profitable.

Having said that, most of the sales seem to have been for only a couple of £k each, so maybe people are selling to cover Christmas expenses, or selling to pay tax bills or simply to reinvest in an ISA. Or perhaps they set themselves a stop loss when they bought in?

[ok,yah] 07/1/2005 19:49

Depressing for holders that some people still selling at these levels dont they know that this always moves quickly on news, which im hoping is positive of course, and just round the corner

[matthu] 06/1/2005 16:09

7,500 traded at 28.5 p - likely a sell?

[matthu] 04/1/2005 18:06

You're right, Tony! So used to seeing selling, I misread the screen.
Can this be the turning point?

[tony5505] 04/1/2005 18:04

Wrong, 3275 bought at 30p, ok.

[matthu] 04/1/2005 16:08

3275 shares sold at 28p this afternoon.

[pugugly] 29/12/2004 15:55

ok,yah. How often do you see this sort of statement in the accounts and then a few month later a Cash Call or other problems. If I had £1,000 for each statement like this which is subsequently proved wrong I would be a very wealthy man. !!
Have a good new year.

[ok,yah] 29/12/2004 11:21

This is one of my tips for 2005 - Think this has been overlooked, having dropped a long way from its float price yet has not disappointed in any way to my knowledge. The interim results were upbeat and the co. completed an earnings enhancing acquisition. The company suggests there will be positive newsflow in the coming months and that it wont be making a cash call.

Prospects

In order to balance our portfolio, we are endeavouring to develop products that
have a shorter lead time in coming to the market. The nutraceutical, biocide and
agrochemical markets provide significant opportunities to do this, and we
believe that the progress we have made in the last half year will enable us to
obtain commercial relationships in each sector in the coming months. Together
with our relationships in pharmaceuticals, we feel that we now have a strong mix
of short, medium and long term opportunities.

We are confident that our revenue opportunities, together with rigorous cost
control, will enable us to attain profitability within the horizon provided by
our current cash balances

[matthu] 22/12/2004 10:36

3000 shares sold at 29p this morning

[matthu] 22/12/2004 07:05

Micap plc announces the commencement of a research study incorporating a Phase 1 Clinical Trial at South Manchester University Hospitals Trust into the effects of Micap encapsulated essential oils and biocide combinations against MRSA



Aromatherapy Oils Could Stamp Out Spread Of MRSA Superbug
22 Dec 2004

Essential oils usually used in aromatherapy have been found to kill the deadly MRSA bacteria according to research carried out at The University of Manchester, UK.

Tests revealed that three essential oils killed MRSA and E. coli as well as many other bacteria and fungi within just two minutes of contact. The oils can easily be blended and made into soaps and shampoos which could be used by hospital staff, doctors and patients in a bid to eradicate the spread of these deadly `super bugs'.

Researchers are now desperately looking for funding to develop their work and carry out a clinical trial. Peter Warn from the University's Faculty of Medicine who worked on the research said: 'We believe that our discovery could revolutionise the fight to combat MRSA and other `super bugs', but we need to carry out a trial and to do that we need a small amount of funding ' around £30,000.

'We are having problems finding this funding because essential oils cannot be patented as they are naturally occurring, so few drug companies are interested in our work as they do not see it as commercially viable. Obviously, we find this very frustrating as we believe our findings could help to stamp out MRSA and save lives,' added Peter, who is based at Hope Hospital.

Essential oils are chemical compounds found within aromatic plants, which the plants use to fight off infections. Researchers tested 40 essential oils against ten of the most deadly bacteria and fungi. Two of these oils killed MRSA and E. coli almost instantly, while a third was shown to act over a longer period of time, meaning that any soaps or shampoos made by blending these three oils would be effective over a period of time.

Jacqui Stringer who is Clinical Lead of Complementary Therapies at the Christie Hospital instigated the research and said: 'The use of plants in medicine is nothing new but some people regard the use of essential oils as unconventional. Our research shows a very practical application which could be of enormous benefit to the NHS and its patients.

'The reason essential oils are so effective is because they are made up of a complex mixture of chemical compounds which the MRSA and other super bug bacteria finds difficult to resist. The problem with current treatments is that they are made of single compounds which MRSA relatively quickly becomes resistant to, so treatment is only successful in around 50% of cases.

'While a wide range of products currently exist to help prevent the spread of MRSA these are often unpleasant for patients as their application can cause skin irritation. MRSA is often carried inside the nose which means that patients often have to insert treatments up their nostrils, whereas these essential oils can simply be inhaled to prevent the patient being at risk,' added Jacqui.

Jacqui works with leukaemia patients at the Christie Hospital using essential oils to help in their treatment. Patients receiving treatment for cancer and leukaemia are often left with weakened immune systems which makes them vulnerable to infection from MRSA.

The National Audit Office estimates that infections such as MRSA kill 5,000 people each year and hospital-acquired infections cost the NHS around £1 billion a year.

[matthu] 21/12/2004 12:47

Look out for the MICAP newsletter which may be posted on their website by about 15:00 today.

[matthu] 16/12/2004 15:56

Well, the mid-price has dropped again today but so far there have been no trades. I would be surprised to see the share price dropping much below 30p, but it really depends on what is going on behind the scenes.

I think the company could probably slow the price drop by putting out another newsletter before Christmas, simply to indicate that all is still on track.

[gjabrj] 16/12/2004 15:46

Where is the share price heading???

[matthu] 15/12/2004 10:07

Small parcel gone through at 30 p again this morning.

[ok,yah] 14/12/2004 18:09

This needs revenues as news alone on tie ups, patents etc, without the promise of cashflow only have a limited effect on the shareprice which tumbles down as cash dwindles

[rambutan2] 14/12/2004 15:53

also still here, for better or worse.

[matthu] 14/12/2004 15:04

No newsletter so far this month - this company needs regular news to support the price.

[goldrush] 14/12/2004 14:57

matthu

Still here too--cannot understand this share price being so low.....

g

[matthu] 14/12/2004 14:42

Sale of 6785 goes through at 30 p

(I think I am probably the only person still reading this thread.)

[matthu] 02/12/2004 16:24

No trading so far today.

[matthu] 02/12/2004 16:23

Another company reports success against MRSA. I think these products are complementary to those being tested by MICAP, which I think include powders which are incorporated into bandages etc.

from
Two products from Bioquell PLC (LSE: BQE.L - news) and Healthcare Enterprise Group PLC have been identified by the UK Department of Health's Rapid Review Panel (RRP) as having potential value in the battle against the MRSA superbug in hospitals.
The panel highlighted Bioquell's RBDS de-contamination system, which use a range of hydrogen peroxide vapour systems to de-contaminate hospital rooms, and Healthcare Enterprise (LSE: HCEG.L - news) 's Ebiox range of hand hygiene products that use non-alcohol based gel for hand cleaning.
However, the panel concluded that the products still need to be subject to further evaluation in an NHS clinical setting.
Bioquell said the results of the trials are encouraging and its will be working with the RRP to agree the basis on which it should supply additional data, which would allow its technology to be introduced into NHS clinical practice following peer reviewed trials and economic appraisal.
Nick Adams, chief executive of Bioquell said: 'The positive recommendations of the RRP should make it significantly easier for us to sell our unique technology to eradicate MRSA and other 'superbugs' in hospitals in the UK and internationally.'
Commenting on the Bioquell product, the panel said: 'The product has been shown to be effective in removing MRSA from the hospital environment. Results suggest that Bioquell hydrogen peroxide vapour is most effective on non-porous surfaces.
(The product) is only appropriate for enclosed rooms and units that can be emptied of patients and staff and sealed for the period of decontamination.
The key question is whether the ability of Bioquell hydrogen peroxide to kill environmental micro-organisms will translate into reduced numbers of healthcare associated infections.'

[matthu] 01/12/2004 10:53

25 k trade at 31 p just gone through

[matthu] 01/12/2004 09:45

Trading this morning at 32 p